Clinical trial NCT00913627: Study Evaluating Ibuprofen 600 mg Extended Release (ER) For Dental Pain
Official title: Ibuprofen 600 Mg Extended Release (er) Single-dose Dental Pain Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Pain
Keywords: Extended-release
ibuprofen
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2009-06-04
Enrollment: 196
Sex: ALL
Minimum age (years): 16
Maximum age (years): 40
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the efficacy and safety of a single dose of an ibuprofen 600 mg extended release formulation in post-operative dental pain. There is concern that the manufacturing process may affect the performance characteristics of the selected prototype. Therefore, two formulations of this prototype manufactured by two different processes, \[roller compaction\] and \[wet granulation\] will be included in this study. The preferred prototype manufactured by two different methods will be compared to placebo and each other. This study will also characterize the pharmacokinetic/pharmacodynamic relationship with these formulations.


Eligibility criteria: Inclusion Criteria:

INCLUSION CRITERIA:

* Males and females 16 to 40 years of age.
* Outpatients who undergo surgical extraction of 1-2 third molars, one of which must be a partial or full bony mandibular impaction and have moderate to severe post-operative pain (confirmed by a VAS score of at least 50 mm on a 100 mm VAS) following surgical extraction;
* Use of only the following preoperative medication(s)/anesthetic(s): short-acting local anesthetic (mepivacaine or lidocaine) with or without vasoconstrictor, nitrous oxide, and/or midazolam;
* Reliable, cooperative, and of adequate intelligence to record the requested information on the analgesic questionnaire form;
* Examined by the attending dentist or physician and medically cleared to participate in the study;
* In general good health and have no contraindications to the study medication.

Exclusion Criteria:

EXCLUSION CRITERIA:

* Pregnancy, as verified by a urine-based pregnancy test, or breast feeding;
* Presence of a serious medical condition (e.g., poorly controlled hypertension, poorly controlled diabetes, significantly impaired cardiac, renal or hepatic function, poorly-controlled hyper- or hypothyroidism);
* Use of a prescription or nonprescription drug with which the administration of ibuprofen or any other NSAID is contraindicated;
* Use of a bisphosphonate (e.g., risedronate \[Actonel\], alendronate \[Fosamax\], or ibandronate \[Boniva\]) in the past 5-years;
* Acute localized dentalveolar infection at the time of surgery that could confound the post-surgical evaluation;
* Females who are of child-bearing potential, or post-menopausal for less than 2 years and not using a medically approved method of contraception (i.e., oral, transdermal, or implanted contraceptives, intrauterine device, diaphragm, condom, abstinence, or surgical sterility), or females who test positive on a urine-based pregnancy test;
* Presence or history (within 2 years of enrollment) of bleeding disorder(s) or peptic ulcer disease;
* History of alcoholism (i.e., on average, consumes 3 or more alcoholic drinks per day) or substance abuse within the last year, or is currently abusing alcohol or other mood-altering drugs (e.g., cannabis). Patients who are taking CNS or other psychotropic drugs (including St. John's Wort, or any other nutritional supplement known to have psychotropic effects) may be enrolled if they have been on stable doses of medication for at least 2 months, will maintain this dose throughout the study, and their condition is judged by the Principal Investigator to be well-controlled;
* Habituation to analgesic drugs (i.e., routine use of oral analgesics 5 or more times per week)
* History of allergic reaction (e.g., asthma, rhinitis, swelling, shock, or hives) to ibuprofen, naproxen, aspirin, or to any other NSAID; or to codeine, hydrocodone, or acetaminophen, or to their combinations;
* Prior use of any type of analgesic or NSAID five half-lives of that drug or less before taking the first dose of study medication, except for pre-anesthetic medication and anesthesia for the procedure;
* Ingestion of any caffeine-containing beverages, chocolate, or alcohol 4 hours or less before taking the first dose of study medication;
* The subject has taken an investigational product or participated in an investigational trial within 30 days of study enrollment;
* The subject has previously participated in this study;
* The subject is a member of the study site staff directly involved with the study, an employee of the Sponsor, or a relative of study site personnel directly involved with the study.

Primary outcomes:
measure: Time-weighted Sum of Pain Intensity Difference Score From 0 to 12 Hours (SPID 0-12)
timeFrame: Baseline (0 hour) to 12 hours post dose
measure: Time-weighted Sum of Pain Intensity Difference Score From 8 to 12 Hours (SPID 8-12)
timeFrame: 8 to 12 hours post dose
Secondary outcomes:
measure: Time to First Perceptible Pain Relief
timeFrame: Baseline to 6 hours
measure: Time to Treatment Failure
timeFrame: Baseline to 24 hours
measure: Percentage of Participants With Treatment Failure
timeFrame: 8, 9, 10, 11, and 12 hours
measure: Time-weighted Sum of Pain Intensity Difference From 0 to 4 Hours (SPID 0-4) and 4 to 8 Hours (SPID 4-8)
timeFrame: 0 to 4 hours and 4 to 8 hours
measure: Time-weighted Sum of Pain Relief and Pain Intensity Difference Scores (SPRID)
timeFrame: 0 to 4 hours, 4 to 8 hours, 8 to 12 hours, and 0 to 12 hours
measure: Time-weighted Sum of Pain Relief Scores (TOTPAR)
timeFrame: 0 to 4 hours, 4 to 8 hours, 8 to 12 hours, and 0 to 12 hours
measure: Percentage of Participants Achieving First Perceptible Relief Confirmed by Meaningful Relief
timeFrame: 15, 30, 45, 60, 90, and 120 minutes and every 60 minutes up to 360 minutes
measure: Time to Meaningful Pain Relief
timeFrame: Baseline to 6 hours
measure: Percentage of Participants Achieving Meaningful Pain Relief
timeFrame: 15, 30, 45, 60, 90, and 120 minutes and every 60 minutes up to 360 minutes
measure: Participant Global Evaluation of Study Medication at 12 Hours
timeFrame: 12 hours
measure: Participant Global Evaluation of Study Medication at 24 Hours
timeFrame: 24 hours
measure: Pain Intensity Difference (PID) Score
timeFrame: 15, 30, 45, 60, 90 minutes and 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, and 24 hours
measure: Pain Relief (PR) Score
timeFrame: 15, 30, 45, 60, 90 minutes and 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, and 24 hours
measure: Pain Relief Combined With Pain Intensity Difference (PRID) Score
timeFrame: 15, 30, 45, 60, 90 minutes and 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, and 24 hours
measure: Peak Pain Relief Score
timeFrame: Baseline to 12 hours
Other outcomes:
Locations:
city: Salt Lake City
country: United States
facility: Jean Brown Research Center
state: Utah
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References: